Kala Pharmaceuticals to Present at Jefferies Healthcare Conference
June 02 2022 - 8:00AM
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of innovative therapies for diseases of the eye,
today announced that it will present at the Jefferies Healthcare
Conference in New York, NY. Members from the management team are
scheduled to participate in a fireside chat on Thursday, June 9,
2022 at 10:30 a.m. ET. Management will also be available for
one-on-one meetings on Wednesday, June 8, 2022 and Thursday, June
9, 2022.
To access the webcast and subsequent archived recording of the
presentation, please visit “Events” in the “Investors” section on
the Kala website at http://kalarx.com.
About Kala Pharmaceuticals, Inc.
Kala is a commercial-stage biopharmaceutical company focused on
the discovery, development, and commercialization of innovative
therapies for diseases of the eye. Kala has applied its
AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery
Technology to two ocular therapies, EYSUVIS® (loteprednol
etabonate ophthalmic suspension) 0.25% and
INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%. On
May 23, 2022, the Company announced that it entered into a
definitive agreement to sell its commercial portfolio and related
intellectual property assets to Alcon Inc. The Company anticipates
the transaction will close in the third quarter of 2022, subject to
certain conditions, including the expiration of the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act and other
customary closing conditions. The Company also has a pipeline of
development programs including a clinical-stage secretome product
candidate, KPI-012, initially targeting persistent corneal
epithelial defects (PCED) and multiple proprietary new chemical
entity (NCE) preclinical development programs targeted to address
unmet medical needs, including both front and back of the eye
diseases. For more information on Kala, please
visit www.kalarx.com.
Investor Contacts:
Jill Steierjill.steier@kalarx.com 781-996-5252
Hannah Deresiewiczhannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Sep 2023 to Sep 2024